drugset / Trial / NCT02897596
Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the efficacy of 12 or 8 weeks treatment with Grazoprevir/Elbasvir in Early Chronic Hepatitis C GT1,4 in HIV co-infected patients and evaluate the safety and tolerability of Grazoprevir + Elbasvir in HIV-HCV co-infected patients.
Timeline
- Start
- 2017-04-28
- Primary completion
- 2019-04-28
- Completion
- 2019-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elbasvir | Small molecule | 50 mg | — |
| Subject | GRAZOPREVIR ANHYDROUS | Small molecule | 100 mg | — |